FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba biotech

"- Ambitious development program for multiple solid tumors with high unmet need, starting with low grade upper tract urothelial cancer (UTUC) - Follows successful clearance of the IND application in Dec 2020 allowing initiation of pivotal Phase 3 clinical trial in patients with low grade UTUC; results to form basis of application for FDA approval."

111621 FDA Grants Fast Track Designation

.

Download • 90KB